Anupam Rasayan India Ltd (ANURAS) is currently trading at 1,232.35 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Anupam Rasayan India Ltd. is an established Indian specialty chemical and custom synthesis manufacturer that undertakes complex multi-step syntheses across life-science related specialty chemicals and performance materials, operating six manufacturing sites with ~30,000+ MT capacity and a DSIR-recognized R&D centre of 90+ scientists to serve global MNC customers. Financially, the company reported consolidated 9MFY26 revenue of ₹17,297 million (up 84% YoY), EBITDA of ₹4,024 million (up 53% YoY) and PAT of ₹1,662 million (up 71% YoY), driven by ramp-up of recently commercialized molecules and stronger execution of a large LOI/contract pipeline that materially increased revenue visibility. Strategically significant moves include a definitive agreement to acquire Jayhawk Fine Chemicals in the U.S. (enterprise value ~$134M; total consideration ~$150M) to secure onshore manufacturing, high-purity tech and customer access, and earlier acquisition of a ~26% stake in Tanfac to backward integrate fluorination feedstocks and reduce supply-chain risk. The company emphasises a differentiated fluorination platform and backward integration, with a disclosed $220–$260 million revenue potential from targeted fluorination series and a separately signed battery-chemicals LOI (LiPF6) valued at ₹3,000 crore, indicating a focused push into high-value, less cyclical end-markets like electronics and battery materials. Operationally, Anupam Rasayan India Ltd. has converted LOIs into commercial revenue, improved asset utilisation and is targeting meaningful working-capital intensity improvements (management target: consolidated working capital days below ~180 by FY27), highlighting execution discipline alongside growth initiatives.

Over the past 52 weeks, Anupam Rasayan India Ltd has traded between a low of ₹1,047.40 and a high of ₹1,415.40. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Anupam Rasayan India Ltd has a market capitalization of approximately 13,976.21. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Anupam Rasayan India Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 62.13 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 13,976.21 Cr, Anupam Rasayan India Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Anupam Rasayan India Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Anupam Rasayan India Ltd is 62.13. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

The company filed its Q1 FY27 unaudited financial results with the BSE on August 15, 2026, for the quarter ended June 30, 2026.

The company filed its Q1 FY27 unaudited financial results with the BSE on August 15, 2026, for the quarter ended June 30, 2026.

Consolidated revenue from operations was ₹654.98 crore and consolidated net profit attributable to owners was ₹38.64 crore for Q1 FY27.

It is a mandatory cash open offer filed with SEBI to buy up to 2,77,26,848 Bliss GVS Pharma shares, representing 26% of the expanded voting share capital.